v3.26.1
Summary of Significant Accounting Policies - Revenue Recognition (Details)
3 Months Ended
Feb. 22, 2026
USD ($)
Apr. 12, 2024
Mar. 31, 2026
USD ($)
Promise
Item
Agreement
Mar. 31, 2026
EUR (€)
Promise
Agreement
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Disaggregation of Product Revenue            
Number of distribution agreements | Agreement     1 1    
Number of promises | Promise     2 2    
Initial term of contract     5 years 5 years    
license fees recognized     $ 43,000   $ 43,000  
Deferred revenue     510,000     $ 552,000
Non-refundable license fee     215,040 € 200,000    
Royalty expense     142,000   39,000  
Revenue     20,272,000   2,214,000  
April 2024 Agreement for Gelclair            
Disaggregation of Product Revenue            
Initial term of contract   5 years        
Royalty expense     $ 142,000      
Woodward            
Disaggregation of Product Revenue            
Number of promises | Promise     3 3    
Mytesi            
Disaggregation of Product Revenue            
Product revenue     $ 918,000   2,100,000  
Number of specialty pharmacies. | Item     5      
License granted     $ 918,000   2,100,000  
Mytesi | Specialty Pharmacies            
Disaggregation of Product Revenue            
Product revenue     11,000   1,700,000  
License granted     11,000   1,700,000  
Canalevia-CA1            
Disaggregation of Product Revenue            
Product revenue     270,000   17,000  
License granted     270,000   17,000  
Neonorm            
Disaggregation of Product Revenue            
Product revenue     7,000   16,000  
License granted     7,000   16,000  
License            
Disaggregation of Product Revenue            
license fees recognized $ 3,000,000   19,000,000      
Revenue recognized     9,000   25,000  
Financial liability     0      
Revenue     $ 19,043,000   $ 43,000